Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate For Parkinson's Disease
Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate For Parkinson's Disease
03/30/22, 5:00 AM
Location
san franciscoMoney raised
$100 million
Industry
biotechnology
science and engineering
health care
Round Type
series c
Neuron23TM Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced it has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing raised to date to $213.5 million. Neuron23's Series A and B investors – Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company) – also participated in the Series C financing round.
Company Info
Location
san francisco, california, united states
Additional Info
Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA, and Munich, Germany.